Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PR interval

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    571 result(s) found for: PR interval. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-011819-20 Sponsor Protocol Number: V00067 CA 201 1A Start Date*: 2009-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study.
    Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057926 Long QT syndrome congenital LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001606-29 Sponsor Protocol Number: INCB39110-309 Start Date*: 2019-04-03
    Sponsor Name:Incyte Corporation
    Full Title: GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
    Medical condition: Moderate or severe cGVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    20.1 10021428 - Immune system disorders 10072160 Chronic graft versus host disease in liver PT
    20.1 10021428 - Immune system disorders 10072158 Chronic graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10072159 Chronic graft versus host disease in skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) SE (Completed) DE (Prematurely Ended) PL (Completed) DK (Completed) ES (Temporarily Halted) GR (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001916-22 Sponsor Protocol Number: Pressure Wire Study Start Date*: 2008-05-02
    Sponsor Name:Central Manchester and Manchester Children's Hospital University NHS Trust
    Full Title: Study to assess the optimum dose of intravenous adenosine in the assessment of fractional flow reserve
    Medical condition: To study the effects of higher dose adenosine on intermediate coronary lesions at coronary angiography which require pressure wire study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004440-19 Sponsor Protocol Number: CLAM320B2202 Start Date*: 2016-03-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regi...
    Medical condition: Treatment of multidrug-resistant pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10070578 Multidrug resistant tuberculosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000128-16 Sponsor Protocol Number: 2011-003 Start Date*: 2012-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001716-59 Sponsor Protocol Number: D4120C00002 Start Date*: 2011-10-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoi...
    Medical condition: Arrhythmia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10003119 Arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004878-99 Sponsor Protocol Number: INCB84344-102 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Biosciences International Sàrl
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants
    Medical condition: Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000830 Acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028549 Myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028553 Myeloid leukaemia, chronic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028552 Myeloid leukaemia, acute LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004013-13 Sponsor Protocol Number: GS-US-313-0124 Start Date*: 2013-10-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Ly...
    Medical condition: Indolent Non-Hodgkin Lymphomas •Follicular lymphoma •Small lymphocytic lymphoma •Lymphoplasmacytic lymphoma (with or without Waldenström macroglobulinemia) •Marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) SE (Prematurely Ended) ES (Completed) HU (Completed) CZ (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003783-27 Sponsor Protocol Number: PN06-CLD-01001 Start Date*: 2006-01-26
    Sponsor Name:PAION Deutschland GmbH
    Full Title: TOLERABILITY OF ENECADIN (INN) IN ACUTE ISCHEMIC STROKE TRIAL - TEST- PHASE IIA : A multicentre, double-blind, randomised, placebo-controlled, dose-escalating parallel- group study to investigate t...
    Medical condition: acute ischemic stoke Based on the results of preclinical studies, enecadin is expected to play an important role in the treatment of acute ischemic stroke and to ameliorate the outcome and prognos...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000981-41 Sponsor Protocol Number: TUXEDO-1 Start Date*: 2020-06-26
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Mdizin I, Onkologie
    Full Title: Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
    Medical condition: HER2-positive Breast Cancer with newly diagnosed or progressing Brain Metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003957-14 Sponsor Protocol Number: KCP-330-023 Start Date*: 2017-03-14
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myelom...
    Medical condition: Relapsed or refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GR (Completed) AT (Completed) CZ (Completed) BE (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003812-36 Sponsor Protocol Number: MORAb-003-011 Start Date*: 2015-06-30
    Sponsor Name:Morphotek Inc
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegyl...
    Medical condition: Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002103-19 Sponsor Protocol Number: CTL-002-001 Start Date*: 2020-12-16
    Sponsor Name:CatalYm GmbH
    Full Title: A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjec...
    Medical condition: Advance-stage, relapsed/refractory solid tumors in non-curable state, that relapsed post or were refractory to a prior anti-PD-1/PD-L1 therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000206-18 Sponsor Protocol Number: PM1183-B-005-14-QT Start Date*: 2015-09-10
    Sponsor Name:PharmaMar S.A., Sociedad Unipersonal
    Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors
    Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003554-33 Sponsor Protocol Number: 20160275 Start Date*: 2017-09-13
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Mye...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) AT (Completed) BE (Completed) HU (Completed) BG (Completed) PL (Completed) CZ (Completed) FR (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001824-33 Sponsor Protocol Number: EFC15935 Start Date*: 2020-10-19
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not ...
    Medical condition: ER (+), HER2 (-) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) FI (Completed) CZ (Completed) AT (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000690-36 Sponsor Protocol Number: TED14856 Start Date*: 2018-12-17
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003715-28 Sponsor Protocol Number: HALO-109-201 Start Date*: 2011-12-08
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002161-36 Sponsor Protocol Number: OP-108 Start Date*: Information not available in EudraCT
    Sponsor Name:Oncopeptides AB
    Full Title: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma
    Medical condition: Patients with relapsed or relapsed-refractory multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) NO (Completed) HU (Completed) FI (Completed) SK (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005855-14 Sponsor Protocol Number: C2L-OCT-01 PR-301 Start Date*: 2007-02-22
    Sponsor Name:Ambrilia Biopharma Inc.
    Full Title: OPEN LABEL, RANDOMIZED STUDY COMPARING THE BIOLOGICAL EFFICACY AND SAFETY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 42 D...
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:30:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA